Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy
Nirsevimab is a new prophylaxis strategy that helps to protect all infants against RSV disease and could substantially reduce the clinical and economic burden of RSV in Italy in infants experiencing their first RSV season.
Authors
- Samira Soudani (ORCID: https://orcid.org/0009-0006-4523-6588)
- Chiara Bini (ORCID: https://orcid.org/0000-0001-5704-6542)
- Eugenio Baraldi (ORCID: https://orcid.org/0000-0002-1829-3652)
- Luigi Orfeo
- Sara Boccalini (ORCID: https://orcid.org/0000-0002-9695-7549)
- Alexia Kieffer (ORCID: https://orcid.org/0009-0004-5735-195X)
- Matthieu Beuvelet (ORCID: https://orcid.org/0000-0001-5450-3613)
- Fabio Midulla (ORCID: https://orcid.org/0000-0001-7476-5266)
- Paolo Bonanni (ORCID: https://orcid.org/0000-0003-2875-3744)
- Barbara Muzii
- Elena Bozzola (ORCID: https://orcid.org/0000-0001-5947-2414)
- Andrea Marcellusi
Institutions
- University of Rome Tor Vergata (IT)
- Sanofi (France) (FR)
- Sanofi (Italy) (IT)
- Bambino Gesù Children's Hospital (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Città della Speranza Foundation (IT)
- University of Florence (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Global & Regional Health Technology Assessment
- Published
- 2025-01-29
- DOI
- https://doi.org/10.33393/grhta.2025.3182
- Citations
- 6
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 8.13